Pyrimidine deoxyribonucleoside potentiation of combination thera

Details Pyrimidine deoxyribonucleoside potentiation of combination thera Pyrimidine deoxyribonucleoside potentiation of combination thera

1994-04-12

1996-03-05

Robinson, Douglas W.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

514 12, 514269, 514889, 514922, 424 854, 424 857, A61K 31505, A61K 3170, A61K 3821

Patent

active

054968100

ABSTRACT:
The applicants have discovered a method of treating malignancies which comprises administering effective amounts of 5-fluorouracil, interferon-.alpha. and a compound formula (I): ##STR1## wherein R is selected is selected from the group consisting of alkyl of 1 to 5 carbon atoms, alkene of 2 to 5 carbon atoms and alkynyl of 2 to 5 carbon atoms; R.sub.1 is 2'-deoxyribofuranosyl.

REFERENCES:
patent: 3954759 (1976-05-01), Anderson et al.
patent: 4895727 (1990-01-01), Allen
Biochemical Pharmacology, vol. 31, No. 22, pp. 3673-3682, 1982, Great Britain, Jan Balzarini et al.
Journal of Medicinal Chemistry, 1978, vol. 21, No. 2, pp. 228-231, Paul F. Torrence et al.
Antimicrobial Agents and Chemotherapy, 1978, vol. 1 13, No. 2, pp. 545-547, E. De Clercq et al.
Pharmacology, Chemotherapy 18:269-273, 1973, pp. 269-273, K. K. Gauri et al.

Affiliated with

Also associated with

Rating

Pyrimidine deoxyribonucleoside potentiation of combination thera does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pyrimidine deoxyribonucleoside potentiation of combination thera, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrimidine deoxyribonucleoside potentiation of combination thera will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1413035